LinkedIn / Modulari-T Bioscience · Jul 2026
Company post promoted a podcast appearance by CEO Tanya E. Borsuk and reiterated Modulari-T's in vivo CAR-T / cell-therapy positioning and Montreal roots.
We teach your immune system to attack and cure cancer
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Montreal-based biotechnology company developing a proprietary 2nd-generation in vivo cell & gene therapy platform built around MARC and MoVe. Public sources describe it as a preclinical, partnership-oriented biotech focused on oncology, autoimmunity, and inflammation; no public GitHub, X, or engineering blog surfaced in the reviewed sources.
Primary product
MARC (Modular Actuation Receptor Complex) plus MoVe (Modular Vector) platform for in vivo cell and gene therapy
Founded
2021
Headquarters
Montreal, Quebec, Canada
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Cell and gene therapy / immunotherapy
Offices
Open Positions
0 jobs at Modulari-T
No open positions
Check back later for new openings